Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
SNN 
Smith & Nephew SNATS Inc (SNN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/27/2025: SNN (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Year Target Price $33.15
Year Target Price $33.15
| 1 | Strong Buy |
| 1 | Buy |
| 2 | Hold |
| 0 | Under performing |
| 0 | Sell |
Analysis of Past Performance
Type Stock | Historic Profit -0.38% | Avg. Invested days 36 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/27/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 13.22B USD | Price to earnings Ratio 32.15 | 1Y Target Price 33.15 |
Price to earnings Ratio 32.15 | 1Y Target Price 33.15 | ||
Volume (30-day avg) - | Beta 0.62 | 52 Weeks Range 23.30 - 30.91 | Updated Date 06/29/2025 |
52 Weeks Range 23.30 - 30.91 | Updated Date 06/29/2025 | ||
Dividends yield (FY) 2.48% | Basic EPS (TTM) 0.94 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 7.09% | Operating Margin (TTM) 18.71% |
Management Effectiveness
Return on Assets (TTM) 5.45% | Return on Equity (TTM) 7.86% |
Valuation
Trailing PE 32.15 | Forward PE 14.12 | Enterprise Value 16019833879 | Price to Sales(TTM) 2.28 |
Enterprise Value 16019833879 | Price to Sales(TTM) 2.28 | ||
Enterprise Value to Revenue 2.76 | Enterprise Value to EBITDA 13.12 | Shares Outstanding 437523008 | Shares Floating 789187417 |
Shares Outstanding 437523008 | Shares Floating 789187417 | ||
Percent Insiders 0.03 | Percent Institutions 7.52 |
Analyst Ratings
Rating 3.75 | Target Price 33.15 | Buy 1 | Strong Buy 1 |
Buy 1 | Strong Buy 1 | ||
Hold 2 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Smith & Nephew SNATS Inc
Company Overview
History and Background
Smith & Nephew, founded in 1856 in Hull, England, is a global medical technology company. SNATS Inc. is the ticker symbol for Smith & Nephew's American Depository Shares. Initially a small pharmacy, it evolved into a leading provider of advanced wound management, sports medicine, and ENT, and orthopaedics products. Significant milestones include numerous acquisitions and product innovations within their respective fields.
Core Business Areas
- Orthopaedics: Offers joint reconstruction systems, trauma products, and enabling technologies such as robotics and navigation.
- Sports Medicine & ENT: Provides arthroscopic technologies, soft tissue repair products, and ENT devices.
- Advanced Wound Management: Delivers products and therapies for wound care, including advanced wound dressings and negative pressure wound therapy.
Leadership and Structure
Smith & Nephew is led by a Chief Executive Officer and a Board of Directors. The company operates through a global organizational structure with regional and functional leadership teams.
Top Products and Market Share
Key Offerings
- Allevyn Life: Advanced wound dressing for pressure ulcers and other chronic wounds. Competitors: Mu00f6lnlycke Health Care, 3M. Revenue included in Advanced Wound Management segment which generates substantial revenue.
- Trigen Meta-Nail: Intramedullary nailing system for fracture fixation. Competitors: Stryker (SYK), Zimmer Biomet (ZBH). Market share is a portion of total orthopaedics market.
- COBLATION Technology: Radiofrequency-based technology for soft tissue ablation in sports medicine and ENT. Competitors: Medtronic (MDT), Olympus.
- JOURNEY II XR Knee System: Advanced knee implant system. Competitors: DePuy Synthes (JNJ), Zimmer Biomet (ZBH). Generates significant revenue within Orthopaedics.
Market Dynamics
Industry Overview
The medical technology industry is characterized by innovation, regulatory scrutiny, and demographic trends such as aging populations. Increasing demand for minimally invasive procedures and advanced technologies drive market growth.
Positioning
Smith & Nephew holds a strong position in orthopaedics, sports medicine, and advanced wound management. Its competitive advantages include a diversified product portfolio, global presence, and strong brand reputation.
Total Addressable Market (TAM)
The total addressable market across Smith & Nephew's segments is estimated in the billions of dollars. They are well-positioned to capture a significant share of this TAM through continued innovation and market expansion.
Upturn SWOT Analysis
Strengths
- Strong brand reputation
- Diversified product portfolio
- Global presence
- Innovation in key product areas
Weaknesses
- Dependence on key products
- Exposure to regulatory changes
- Pricing pressures
- Potential for product recalls
Opportunities
- Expansion into emerging markets
- Development of new technologies
- Strategic acquisitions
- Partnerships with healthcare providers
Threats
- Increased competition
- Economic downturns
- Changes in healthcare policies
- Technological obsolescence
Competitors and Market Share
Key Competitors
- JNJ
- ZBH
- SYK
- MDT
- BSX
Competitive Landscape
Smith & Nephew competes with larger players with wider product portfolios. Its advantages include a focus on specific therapeutic areas, while disadvantages include a smaller overall size.
Major Acquisitions
Osiris Therapeutics
- Year: 2019
- Acquisition Price (USD millions): 340
- Strategic Rationale: Acquired to bolster its Advanced Wound Management portfolio with regenerative medicine technologies.
Growth Trajectory and Initiatives
Historical Growth: Historical growth trends would be based on public financial reports on Smith & Nephew SNATS Inc.
Future Projections: Future projections for Smith & Nephew SNATS Inc's future growth are based on analyst estimates from reputable financial firms.
Recent Initiatives: Recent strategic initiatives would need to be verified through company documentation.
Summary
Smith & Nephew has a strong market position and diversified product line which help mitigate revenue risks, but its size compared to competitors poses challenges. The company's focus on innovation and strategic acquisitions can fuel future growth. Keeping abreast of competitive and legislative environments are essential to maintaining momentum. The overall success of Smith & Nephew relies on expanding into new markets while efficiently managing product costs.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- Analyst Reports
- Financial News Outlets
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market conditions and company performance can change rapidly.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Smith & Nephew SNATS Inc
Exchange NYSE | Headquaters - | ||
IPO Launch date 1999-11-16 | CEO & Director Dr. Deepak S. Nath Ph.D. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 17349 | Website https://www.smith-nephew.com |
Full time employees 17349 | Website https://www.smith-nephew.com | ||
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. It operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.